Company intelligence / Profile preview

Aesica

Newcastle upon Tyne, United Kingdom

Ownership: Private
Employees: ~1300
Development stage: Other

Overview

Aesica was a European CDMO specializing in APIs and finished dose manufacturing, supplying top pharmaceutical companies and producing widely used drugs such as flurbiprofen; it operated six sites and was acquired in 2014 by Consort Medical for approximately $370M, then later integrated into the parent company's device/pharma business.

Therapeutic areas: CardiovascularImmunologyEndocrinologyRheumatologyInfectious DiseasesOtherHematology
Modalities: Small molecule
Industry: Contract Manufacturing Organization

Partnerships

Top 20 global pharmaceutical companies

Beyond the preview

Go deeper on Aesica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aesica.

Explore the full profile